Category: Globus Medical
Globus Medical shares are up this morning on preliminary 4th-quarter sales numbers that topped expectations and blew away the sluggish overall spinal implant market.
Globus Medical (NYSE:GMED) blew the doors off of the sluggish growth rate for the spinal implant market during the 4th quarter, topping Wall Street's expectations and sending share prices up today.
Globus Medical gets into the robotic surgery arena with the acquisition of Excelsius Surgical and its positioning platform for spine and brain procedures.
Johnson & Johnson's Synthes subsidiary wins a round in its lawsuit against a former sales rep who jumped ship for rival Globus Medical, when a Pennsylvania appeals court rules that the lower court mistakenly applied California law in denying a Synthes bid for a preliminary injunction.
Globus Medical shares gain on strong 3rd-quarter results and increased earnings guidance.
Globus Medical (NYSE:GMED) shares gained this week after the medical device company reported strong 3rd-quarter results ahead of Wall Street's expectations and raised its earnings outlook for the rest of the year.
Globus Medical says the FDA issued a warning letter over its MicroFuse bone-growth putty.
Globus Medical (NYSE:GMED) said the FDA issued a warning letter last month over its MicroFuse bone-growth putty, sending share prices down today on Wall Street.
Johnson & Johnson's DePuy Synthes subsidiary goes after a trio of ex-sales reps now working for rival Globus Medical in Texas.
A $16 million patent infringement loss to Johnson & Johnson's DePuy-Synthes subsidiary pushes Globus Medical's 2nd-quarter earnings down, but share prices tick up as it beats Wall Street's expectations.
Globus Medical (NYSE:GMED) shares rose more than 2% last week despite a 61% 2nd-quarter profit slide after the medical device company reported earnings above Wall Street's forecast and confirmed its outlook for the rest of the year.